NeuroSense (NRSN) CFO Or Eisenberg reports 573,126 shares and warrants on Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
NeuroSense Therapeutics Ltd. filed an initial Form 3 for Chief Financial Officer Or Eisenberg, detailing his existing equity interests in the company. The filing reports direct ownership of 573,126 Ordinary Shares, along with fully vested options and warrants over additional Ordinary Shares.
The Form 3 shows options to purchase 21,000 Ordinary Shares at an exercise price of $0.033 per share, expiring on June 21, 2031, which are noted as fully vested and exercisable. It also lists warrants to purchase 66,666 Ordinary Shares at an exercise price of $0.75 per share, expiring on August 14, 2029, acquired in an August 15, 2024 private placement.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Eisenberg Or
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Warrants to purchase Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Options to Purchase Ordinary Shares — 21,000 shares (Direct);
Warrants to purchase Ordinary Shares — 66,666 shares (Direct);
Ordinary Shares — 341,508 shares (Direct)
Footnotes (1)
- To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee. These restricted shares vest in accordance with the following vesting schedule: (i) 75% vest on April 16, 2027, and (ii) the remaining portion shall vest on October 16, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person. These options are fully vested and exercisable. On August 15, 2024, the Reporting Person acquired (i) 66,666 ordinary shares of the Company, no par value per share ("Ordinary Shares"), and (ii) warrants to purchase up to 66,666 Ordinary Shares at a combined purchase price of $0.75 per Ordinary Share and accompanying warrant, in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.
Key Figures
Direct Ordinary Shares holding: 573,126 shares
Options underlying shares: 21,000 shares
Option exercise price: $0.033 per share
+5 more
8 metrics
Direct Ordinary Shares holding
573,126 shares
Reported direct ownership on Form 3
Options underlying shares
21,000 shares
Options to purchase Ordinary Shares
Option exercise price
$0.033 per share
Exercise price for 21,000-share option grant
Option expiration
June 21, 2031
Expiration date of options at $0.033
Warrants underlying shares
66,666 shares
Warrants to purchase Ordinary Shares
Warrant exercise price
$0.75 per share
Exercise price for 66,666-share warrant position
Warrant expiration
August 14, 2029
Expiration date of warrants at $0.75
Private placement purchase price
$0.75 per share and warrant
Combined purchase price in August 15, 2024 transaction
Key Terms
Form 3, Options to Purchase Ordinary Shares, warrants to purchase Ordinary Shares, 2018 Share Incentive Plan, +2 more
6 terms
Form 3 regulatory
"NeuroSense Therapeutics Ltd. filed an initial Form 3 for Chief Financial Officer Or Eisenberg"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Section 102 of the Israeli Tax Ordinance regulatory
"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued"
private placement transaction financial
"in a private placement transaction pursuant to an exemption from the registration requirements"
FAQ
What does the Form 3 for NeuroSense Therapeutics (NRSN) disclose about Or Eisenberg?
The Form 3 discloses CFO Or Eisenberg’s existing equity interests in NeuroSense Therapeutics. It reports direct ownership of 573,126 Ordinary Shares and additional derivative positions through options and warrants linked to the company’s Ordinary Shares.
What stock options for NeuroSense (NRSN) does Or Eisenberg report on Form 3?
Or Eisenberg reports options to purchase 21,000 NeuroSense Ordinary Shares at an exercise price of $0.033 per share, expiring June 21, 2031. A footnote states these options are fully vested and exercisable, meaning they can be converted into Ordinary Shares at that price.